We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-16.07%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.14B
AUM Growth
-$212M
Cap. Flow
+$85.4M
Cap. Flow %
7.49%
Top 10 Hldgs %
46.56%
Holding
206
New
51
Increased
51
Reduced
18
Closed
36

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$27.8M
2
HUM icon
Humana
HUM
+$19.1M
3
XLRN
Acceleron Pharma
XLRN
+$15.3M
4
QTNT
Quotient Limited Ordinary Shares
QTNT
+$13.2M
5
MDVN
MEDIVATION, INC.
MDVN
+$12.3M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$68.4M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$12.9M
3
BAX icon
Baxter International
BAX
+$10.1M
4
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$8.54M
5
NVRO
NEVRO CORP.
NVRO
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.87%
2 Consumer Staples 0.6%
3 Consumer Discretionary 0.11%
4 Industrials 0.04%
5 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELDN icon
76
Eledon Pharmaceuticals
ELDN
$272M
$2.72M 0.24%
2,996
– –
CEMP
77
DELISTED
Cempra, Inc.
CEMP
$2.63M 0.23%
+150,000
New +$2.72M
ARDX icon
78
Ardelyx
ARDX
$989M
$2.46M 0.22%
315,955
– –
WVE icon
79
Wave Life Sciences
WVE
$1.03B
$2.44M 0.21%
+176,000
New +$2.46M
KA
80
DELISTED
Kineta, Inc. Common Stock
KA
$2.41M 0.21%
+1,786
New +$1.97M
CRBP icon
81
Corbus Pharmaceuticals
CRBP
$219M
$2.26M 0.2%
41,667
– –
RGLS
82
DELISTED
Regulus Therapeutics
RGLS
$2.26M 0.2%
+2,712
New +$2.16M
UTHR icon
83
United Therapeutics
UTHR
$22.2B
$2.23M 0.2%
+20,000
New +$2.53M
TARA icon
84
Protara Therapeutics
TARA
$231M
$2.13M 0.19%
6,875
– –
MGCD
85
DELISTED
MGC Diagnostics Corporation
MGCD
$2.04M 0.18%
336,287
– –
DXCM icon
86
DexCom
DXCM
$33.6B
$1.8M 0.16%
+105,896
New +$1.77M
EIGR
87
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.76M 0.15%
+3,497
New +$1.74M
PETX
88
DELISTED
Aratana Therapeutics, Inc.
PETX
$1.61M 0.14%
+291,800
New +$1.1M
CBPO
89
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$1.6M 0.14%
+14,000
New +$1.64M
ADYX
90
DELISTED
Adynxx Inc
ADYX
$1.57M 0.14%
32,033
– –
XENE icon
91
Xenon Pharmaceuticals
XENE
$6.18B
$1.44M 0.13%
205,800
– –
CSBR icon
92
Champions Oncology
CSBR
$68.4M
$1.36M 0.12%
372,597
– –
DSCI
93
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$1.34M 0.12%
432,884
+30,000
+7% +$100K
NVTA
94
DELISTED
Invitae Corporation
NVTA
$1.21M 0.11%
118,366
-25,000
-17% -$199K
AGRX
95
DELISTED
Agile Therapeutics
AGRX
$1.09M 0.1%
+88
New +$1.14M
NEOS
96
DELISTED
Neos Therapeutics, Inc
NEOS
$1.08M 0.09%
100,000
-42,603
-30% -$449K
BCLI
97
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.07M 0.09%
+26,667
New +$980K
VXX
98
DELISTED
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
$1.06M 0.09%
+3,750
New +$1.41M
ABEOW
99
DELISTED
Abeona Therapeutics Inc Warrant
ABEOW
$1.03M 0.09%
1,259,636
– –
GWPH
100
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$946K 0.08%
+13,109
New +$719K
2 3
4
5 6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q1 2016 Portfolio in Review

As of Q1 2016, Perceptive Advisors held 206 positions worth $1.14B, down 16% from $1.35B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors deployed $85.4M of net new capital in Q1 2016, opening 51 new positions and adding to 51 existing holdings. Its largest new stake was Humana: 110,000 shares worth $20.1M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $12.9M trimmed.

  • Perceptive Advisors's largest Q1 2016 buy was Humana: 110,000 shares worth $20.1M.
  • Perceptive Advisors added most to Sarepta Therapeutics in Q1 2016, an estimated $27.8M increase.
  • Perceptive Advisors's biggest Q1 2016 reduction was Teva Pharmaceuticals, cutting an estimated $12.9M.
  • Perceptive Advisors fully exited DYAX CORPORATION in Q1 2016, selling an estimated $68.4M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $1.14B portfolio in Q1 2016.
  • Perceptive Advisors opened 51 new positions and closed 36 in Q1 2016.
  • Perceptive Advisors's portfolio value fell 16% quarter-over-quarter to $1.14B.

Based on Perceptive Advisors's 13F filing for Q1 2016, filed 16 May 2016.